KDM3A and breast carcinoma: Additionally, inhibiting α-KG dehydrogenase enhances α-KG levels and TET activities, restoring DNA demethylation and ameliorating the progression of T2DM and breast cancer.344,345 Similarly, IOX1, an inhibitor of α-KG oxygenases and a potent inhibitor of lysine demethylase 3 A (KDM3A) and KDM4A, has been found to reduce TET enzymatic activities in helper T cells, emerging as a potential epigenetic drug for various autoimmune diseases.346 In conclusion, α-KG represents a promising target for TET-targeted drug development that should be further explored in clinical trials.